AMSilk to showcase its biofabricated yarns at Première Vision
AMSilk GmbH announces that it will be making its first appearance at Première Vision Paris, the largest textile trade show in Europe, from the 2-4 July 2024.
We’ve got news for you!
Follow us on our mission to lead the change towards better and more sustainable products in the new era of biomaterials. Here you will find a summary of our latest news and press releases. If you have any further questions please reach out to:
Isabel Rosenberger
Senior Manager Marketing & Communication
E-Mail: pr@amsilk.com
Tel: (+49) 89 5795393-0
AMSilk GmbH announces that it will be making its first appearance at Première Vision Paris, the largest textile trade show in Europe, from the 2-4 July 2024.
AMSilk today announces that it has completed an independent ‘Cradle-to-Gate’ Life Cycle Assessment (LCA) comparing the environmental footprint of AMSilk Ultrafine Fiber with mulberry silk across five environmental indicators
AMSilk today announces the appointments of Ralph Fraundorfer and Ctibor Kohutovic to its Management Board starting immediately.
AMSilk today announces the appointments of Ralph Fraundorfer and Ctibor Kohutovic to its Management Board starting immediately.
After a year of working together, BRAIN Biotech and AMSilk have specifically optimized a natural structural protein and subsequently registered the first PCT patent (“Patent Cooperation Treaty”) for this process.
New protein production strain delivers unprecedented yield with greater efficiency and lower costs
AMSilk announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO). Gudrun will be responsible for AMSilk’s protein and strain strategy as well as bridging science and business development.
Don't miss the chance to connect with AMSilk, as we join the panel at SynBioBeta Global Synthetic Biology Conference. The SynBioBeta 2023 event brings together the most innovative pioneers in bioindustrials who are passionate about transforming society and our planet for the better.
AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announced it has successfully raised an additional EUR 25 million in an extended Series C financing led by existing investor ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital.
Creating a better future with biotechnology - this vision is shared by BRAIN Biotech AG (BRAIN Biotech), a leader in the development and manufacture of bio-based solutions and products for industry, and AMSilk GmbH (AMSilk), the world's first industrial supplier of innovative biomaterials for more sustainable applications in the textile, medical and consumer goods industries.